Anhui Fengyuan Pharmaceutical Co Ltd (000153) — Strategic Asset Allocation Index
Anhui Fengyuan Pharmaceutical Co Ltd (000153) has a Strategic Asset Allocation Index of 79.1% as of September 2023. Strategic assets (PP&E of CN¥1.49 Billion plus long-term investments of CN¥-) total CN¥1.49 Billion, measured against net assets of CN¥1.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Anhui Fengyuan Pharmaceutical Co Ltd Strategic Asset Allocation Index (2000–2022)
This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of September 2023, the index stands at 79.1%, representing strategic assets of CN¥1.49 Billion against net assets of CN¥1.89 Billion CNY. Explore Anhui Fengyuan Pharmaceutical Co Ltd cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Anhui Fengyuan Pharmaceutical Co Ltd (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Anhui Fengyuan Pharmaceutical Co Ltd from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Anhui Fengyuan Pharmaceutical Co Ltd (000153) total market value.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 83.3% | CN¥1.46 Billion | CN¥1.46 Billion | CN¥- | CN¥1.75 Billion | ▲ +4.7 pp |
| 2021 | 78.5% | CN¥1.22 Billion | CN¥1.22 Billion | CN¥- | CN¥1.56 Billion | ▲ +6.4 pp |
| 2020 | 72.1% | CN¥1.04 Billion | CN¥1.04 Billion | CN¥- | CN¥1.45 Billion | ▲ +6.0 pp |
| 2019 | 66.1% | CN¥877.11 Million | CN¥877.11 Million | CN¥- | CN¥1.33 Billion | ▼ -13.4 pp |
| 2018 | 79.5% | CN¥1.03 Billion | CN¥806.55 Million | CN¥220.26 Million | CN¥1.29 Billion | ▲ +1.8 pp |
| 2017 | 77.7% | CN¥948.62 Million | CN¥817.33 Million | CN¥131.29 Million | CN¥1.22 Billion | ▼ -7.8 pp |
| 2016 | 85.5% | CN¥985.88 Million | CN¥856.21 Million | CN¥129.66 Million | CN¥1.15 Billion | ▼ -0.7 pp |
| 2015 | 86.3% | CN¥1.02 Billion | CN¥913.55 Million | CN¥107.91 Million | CN¥1.18 Billion | ▲ +10.3 pp |
| 2014 | 76.0% | CN¥871.22 Million | CN¥871.22 Million | CN¥- | CN¥1.15 Billion | ▼ -3.9 pp |
| 2013 | 79.8% | CN¥841.75 Million | CN¥841.75 Million | CN¥- | CN¥1.05 Billion | ▼ -14.9 pp |
| 2012 | 94.7% | CN¥734.19 Million | CN¥734.19 Million | CN¥- | CN¥775.01 Million | ▲ +8.0 pp |
| 2011 | 86.7% | CN¥663.57 Million | CN¥663.57 Million | CN¥- | CN¥765.24 Million | ▲ +1.9 pp |
| 2010 | 84.8% | CN¥639.34 Million | CN¥639.34 Million | CN¥- | CN¥753.81 Million | ▲ +1.2 pp |
| 2009 | 83.6% | CN¥567.19 Million | CN¥567.19 Million | CN¥- | CN¥678.70 Million | ▲ +0.6 pp |
| 2008 | 83.0% | CN¥542.99 Million | CN¥542.99 Million | CN¥- | CN¥654.09 Million | ▼ -0.3 pp |
| 2007 | 83.3% | CN¥532.03 Million | CN¥532.03 Million | CN¥- | CN¥638.89 Million | ▲ +3.4 pp |
| 2006 | 79.9% | CN¥495.48 Million | CN¥495.48 Million | CN¥- | CN¥620.49 Million | ▲ +2.7 pp |
| 2005 | 77.2% | CN¥462.59 Million | CN¥462.59 Million | CN¥- | CN¥599.59 Million | ▲ +1.0 pp |
| 2004 | 76.1% | CN¥449.98 Million | CN¥449.98 Million | CN¥- | CN¥591.07 Million | ▼ -1.5 pp |
| 2003 | 77.6% | CN¥447.06 Million | CN¥447.06 Million | CN¥- | CN¥576.00 Million | ▲ +4.8 pp |
| 2002 | 72.8% | CN¥408.47 Million | CN¥408.47 Million | CN¥- | CN¥560.87 Million | ▲ +7.9 pp |
| 2001 | 64.9% | CN¥348.19 Million | CN¥348.19 Million | CN¥- | CN¥536.15 Million | ▲ +33.2 pp |
| 2000 | 31.8% | CN¥169.23 Million | CN¥169.23 Million | CN¥- | CN¥532.50 Million | — |